S&P 500   3,331.39 (-0.53%)
DOW   27,276.98 (-0.40%)
QQQ   270.01 (-1.69%)
AAPL   441.91 (-3.01%)
MSFT   211.30 (-2.33%)
FB   267.09 (+0.68%)
GOOGL   1,491.30 (-0.91%)
AMZN   3,146.95 (-2.42%)
NVDA   441.83 (-2.56%)
CGC   16.68 (-4.79%)
BABA   249.22 (-6.20%)
TSLA   1,421.03 (-4.60%)
MU   48.20 (-1.03%)
GE   6.40 (+0.95%)
AMD   83.24 (-4.00%)
T   29.94 (+0.30%)
F   6.83 (-1.44%)
ACB   10.04 (-2.62%)
GILD   68.97 (+0.23%)
NFLX   487.33 (-4.27%)
DIS   129.22 (-1.22%)
BAC   25.98 (+2.00%)
BA   169.25 (-1.71%)
S&P 500   3,331.39 (-0.53%)
DOW   27,276.98 (-0.40%)
QQQ   270.01 (-1.69%)
AAPL   441.91 (-3.01%)
MSFT   211.30 (-2.33%)
FB   267.09 (+0.68%)
GOOGL   1,491.30 (-0.91%)
AMZN   3,146.95 (-2.42%)
NVDA   441.83 (-2.56%)
CGC   16.68 (-4.79%)
BABA   249.22 (-6.20%)
TSLA   1,421.03 (-4.60%)
MU   48.20 (-1.03%)
GE   6.40 (+0.95%)
AMD   83.24 (-4.00%)
T   29.94 (+0.30%)
F   6.83 (-1.44%)
ACB   10.04 (-2.62%)
GILD   68.97 (+0.23%)
NFLX   487.33 (-4.27%)
DIS   129.22 (-1.22%)
BAC   25.98 (+2.00%)
BA   169.25 (-1.71%)
S&P 500   3,331.39 (-0.53%)
DOW   27,276.98 (-0.40%)
QQQ   270.01 (-1.69%)
AAPL   441.91 (-3.01%)
MSFT   211.30 (-2.33%)
FB   267.09 (+0.68%)
GOOGL   1,491.30 (-0.91%)
AMZN   3,146.95 (-2.42%)
NVDA   441.83 (-2.56%)
CGC   16.68 (-4.79%)
BABA   249.22 (-6.20%)
TSLA   1,421.03 (-4.60%)
MU   48.20 (-1.03%)
GE   6.40 (+0.95%)
AMD   83.24 (-4.00%)
T   29.94 (+0.30%)
F   6.83 (-1.44%)
ACB   10.04 (-2.62%)
GILD   68.97 (+0.23%)
NFLX   487.33 (-4.27%)
DIS   129.22 (-1.22%)
BAC   25.98 (+2.00%)
BA   169.25 (-1.71%)
S&P 500   3,331.39 (-0.53%)
DOW   27,276.98 (-0.40%)
QQQ   270.01 (-1.69%)
AAPL   441.91 (-3.01%)
MSFT   211.30 (-2.33%)
FB   267.09 (+0.68%)
GOOGL   1,491.30 (-0.91%)
AMZN   3,146.95 (-2.42%)
NVDA   441.83 (-2.56%)
CGC   16.68 (-4.79%)
BABA   249.22 (-6.20%)
TSLA   1,421.03 (-4.60%)
MU   48.20 (-1.03%)
GE   6.40 (+0.95%)
AMD   83.24 (-4.00%)
T   29.94 (+0.30%)
F   6.83 (-1.44%)
ACB   10.04 (-2.62%)
GILD   68.97 (+0.23%)
NFLX   487.33 (-4.27%)
DIS   129.22 (-1.22%)
BAC   25.98 (+2.00%)
BA   169.25 (-1.71%)
Log in

NASDAQ:RAPTRAPT Therapeutics Stock Price, Forecast & News

$24.02
+1.04 (+4.53 %)
(As of 08/7/2020 02:35 PM ET)
Add
Compare
Today's Range
$22.95
Now: $24.02
$24.50
50-Day Range
$21.60
MA: $26.51
$32.18
52-Week Range
$10.52
Now: $24.02
$51.21
Volume2,979 shs
Average Volume136,322 shs
Market Capitalization$585.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RAPT
CUSIPN/A
CIKN/A
Phone650-489-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.35 per share

Profitability

Miscellaneous

Employees64
Market Cap$585.37 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable
$24.02
+1.04 (+4.53 %)
(As of 08/7/2020 02:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RAPT News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RAPT Therapeutics (NASDAQ:RAPT) Frequently Asked Questions

How has RAPT Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

RAPT Therapeutics' stock was trading at $15.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RAPT stock has increased by 52.7% and is now trading at $24.02.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of RAPT Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for RAPT Therapeutics
.

When is RAPT Therapeutics' next earnings date?

RAPT Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for RAPT Therapeutics
.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics (NASDAQ:RAPT) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.13. The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $2.50 million.
View RAPT Therapeutics' earnings history
.

What price target have analysts set for RAPT?

6 analysts have issued 12 month price targets for RAPT Therapeutics' stock. Their forecasts range from $35.00 to $51.00. On average, they anticipate RAPT Therapeutics' share price to reach $41.33 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for RAPT Therapeutics
.

Has RAPT Therapeutics been receiving favorable news coverage?

News articles about RAPT stock have been trending positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RAPT Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about RAPT Therapeutics
.

Are investors shorting RAPT Therapeutics?

RAPT Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totaling 923,800 shares, an increase of 11.1% from the July 15th total of 831,200 shares. Based on an average daily trading volume, of 160,300 shares, the days-to-cover ratio is presently 5.8 days. Approximately 7.0% of the shares of the stock are short sold.
View RAPT Therapeutics' Current Options Chain
.

Who are some of RAPT Therapeutics' key competitors?

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include Slack (WORK), Cisco Systems (CSCO), Myovant Sciences (MYOV), ServiceNow (NOW), NVIDIA (NVDA), Applied Genetic Technologies (AGTC), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Amarin (AMRN) and Broadcom (AVGO).

Who are RAPT Therapeutics' key executives?

RAPT Therapeutics' management team includes the following people:
  • Dr. Brian Russell Wong, CEO, Pres & Director (Age 47)
  • Mr. Eric J. Hall CFA, Interim CFO & Sec. (Age 64)
  • Steve Young Ph.D., VP of Technology
  • Dr. Dirk G. Brockstedt Ph.D., Chief Scientific Officer (Age 50)
  • Ms. Erin Campany, VP of HR (Age 52)

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

What is RAPT Therapeutics' stock symbol?

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Regents of The University of California (6.45%), Asymmetry Capital Management L.P. (0.14%), Virtus ETF Advisers LLC (0.07%), UBS Group AG (0.06%), New York State Common Retirement Fund (0.04%) and SG Americas Securities LLC (0.02%). Company insiders that own RAPT Therapeutics stock include Brian Russell Wong, Dirk G Brockstedt, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Wendye Robbins and William Ho.
View institutional ownership trends for RAPT Therapeutics
.

Which institutional investors are buying RAPT Therapeutics stock?

RAPT stock was purchased by a variety of institutional investors in the last quarter, including Regents of The University of California, Asymmetry Capital Management L.P., Virtus ETF Advisers LLC, UBS Group AG, New York State Common Retirement Fund, SG Americas Securities LLC, Parallel Advisors LLC, and Ameritas Investment Partners Inc.. Company insiders that have bought RAPT Therapeutics stock in the last two years include Brian Russell Wong, Group Ii Lp Column, and Wendye Robbins.
View insider buying and selling activity for RAPT Therapeutics
.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RAPT Therapeutics' stock price today?

One share of RAPT stock can currently be purchased for approximately $24.02.

How big of a company is RAPT Therapeutics?

RAPT Therapeutics has a market capitalization of $585.37 million. The company earns $-43,000,000.00 in net income (profit) each year or ($9.89) on an earnings per share basis. RAPT Therapeutics employs 64 workers across the globe.

What is RAPT Therapeutics' official website?

The official website for RAPT Therapeutics is www.flxbio.com.

How can I contact RAPT Therapeutics?

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-489-9000 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.